An international study led by the University of Colorado Cancer Center has uncovered why a widely used treatment for acute myeloid leukemia (AML) doesn’t work for everyone. The findings could help doctors better match patients with the therapies most likely to work for them.
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
PickUp USA Fitness Set to Open a New Franchise Location in Colorado LOS ANGELES, June 21, 2022 /PRNewswire/ — PickUp USA Fitness (www.pickupusafitness.com) will be opening their newest franchise location in Greenwood Village in July. […]
As more states create dedicated boards to cap the costs of medicines, some drugmakers and their allies are pushing back with a controversial tactic — lobbying for legislation to set exemptions for so-called orphan drugs, […]
FY 2023 Revenue Increased 17% to $184.3 Million Company Announces Additional $20 Million Stock Repurchase Plan ENGLEWOOD, Colo., Feb. 29, 2024 /PRNewswire/ — Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the […]
Copyright © 2026 Biotech Networks
